BioSpace News Archive

Ribbon Biolabs, the DNA synthesis company, announced the appointment of Jodi Barrientos as Chief Business Officer.

Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced the appointment of Susan Altschuller, Ph.D. as chief financial officer, effective May 15, 2023.

Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the 2023 RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023 at 4:35 p.m. ET at the InterContinental Barclay in New York, NY.

Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today reported financial results for the first quarter ending March 31, 2023, and highlighted recent business updates.

PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three months ended March 31, 2023.

Bio-Techne announced the launch of two new RNAscope™ in situ Hybridization Probes Kappa and Lambda as analyte specific reagents for the detection of immunoglobulin kappa and lambda light chains mRNA in B-cells.

Micron Biomedical announced it has secured an additional $3 million investment from J2 Ventures, bringing its total Series A funding to $17 million.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2023 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 1, 2023.

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, reported financial results for the quarter ended March 31, 2023, and provided a business update.

Virpax ® Pharmaceuticals, Inc. today announced that it has been invited to present its Molecular Envelope Technology (MET), as well as its AnQlar TM product candidate for viral inhibition that utilizes MET, at the June 8, 2023, virtual CB Tech Watch Seminar.